TITLE

High-Dose Recombinant Canarypox Vaccine Expressing HIV-1 Protein, in Seronegative Human Subjects

AUTHOR(S)
Goepfert, Paul A.; Horton, Helen; McElrath, M. Juliana; Gurunathan, Sanjay; Ferrari, Guido; Tomaras, Georgia D.; Montefiori, David C.; Allen, Mary; Ya-Lin Chiu; Spearman, Paul; Fuchs, Jonathan D.; Koblin, Beryl A.; Blattner, William A.; Frey, Sharon; Keefer, Michael C.; Baden, Lindsey R.; Corey, Lawrence
PUB. DATE
October 2005
SOURCE
Journal of Infectious Diseases;10/1/2005, Vol. 192 Issue 7, p1249
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. In clinical trials, canarypox ALVAC-human immunodeficiency virus (HIV) vaccines have been shown to elicit human HIV-specific cytotoxic T lymphocyte (CTL) responses in some but not all healthy uninfected adults. Methods. A clinical trial was conducted to examine whether the vaccine vCP1452 would elicit a greater HIVspecific CTL response when given at a dose of 108.0 TCID50 (60 participants) than when given at the regular dose, 107.26 TCID50 (40 participants); as a control, a placebo vaccine preparation also was administered (10 participants). Results. Two weeks after the last vaccination in a series, HIV-specific CTL responses were not significantly different when measured by either chromium-release assay (8% and 16% in the high- and regular-dose recipients, respectively) or interferon-γ ELISpot assay (8% and 15% in the high- and regular-dose recipients, respectively); moreover, recipients of the higher dose had greater local and systemic reactions (P < .001 ). Conclusions. High reactogenicity associated with an increased dose of vCP1452 negates the need for further evaluation of this strategy to boost the frequency of HIV-specific CTL response in seronegative human subjects. Development of highly immunogenic canarypox vectors requires further work to optimize vector and insert design, as well as novel ways to increase dosage and to reduce reactogenicity.
ACCESSION #
18331147

 

Related Articles

  • Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens. Asmuth, David M.; Brown, Elizabeth L.; DiNubile, Mark J.; Xiao Sun; del Rio, Carlos; Harro, Clayton; Keefer, Michael C.; Kublin, James G.; Dubey, Sheri A.; Kierstead, Lisa S.; Casimiro, Danilo R.; Shiver, John W.; Robertson, Michael N.; Quirk, Erin K.; Mehrotra, Devan V. // Journal of Infectious Diseases;1/1/2010, Vol. 201 Issue 1, p132 

    Background. We report composite results from the Merck phase I program of near-consensus clade B human immunodeficiency virus (HIV) type 1 gag vaccines. Methods. Healthy HIV-uninfected adults were enrolled in 6 blinded placebo-controlled studies evaluating the immunogenicity of (1) a 4-dose...

  • Old vaccine trial draws new scrutiny. McEnery, Regina // VAX; 

    The article offers information related to premature termination of a Phase IIb Human Immunodeficiency Virus (HIV) vaccine trial in the U.S. known as HVTN 505, which has led to the fresh analysis of termination of a Phase IIb study from South Africa which was halted a few months after it started...

  • Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India. Mehendale, Sanjay; Sahay, Seema; Thakar, Madhuri; Sahasrabuddhe, Sushant; Kakade, Meghana; Shete, Ashwini; Shrotri, Aparna; Spentzou, Aggeliki; Tarragona, Tony; Stevens, Gwynneth; Kochhar, Sonali; Excler, John Louis; Fast, Pat; Paranjape, Ramesh // Indian Journal of Medical Research;Aug2010, Vol. 132 Issue 2, p168 

    Background & objective: A phase 1 trial of adeno-associated virus based HIV-1 subtype C vaccine (tgAAC09) was conducted at two sites in Germany and Belgium and one site in India. This paper reports the safety and immunogenicity of tgAAC09 in healthy adult Indian volunteers. Methods: Between...

  • A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172). Kibuuka, Hannah; Kimutai, Robert; Maboko, Leonard; Sawe, Fred; Schunk, Mirjam S.; Arne Kroidl; Shaffer, Douglas; Eller, Leigh Anne; Kibaya, Rukia; Eller, Michael A.; Schindler, Karin B.; Schuetz, Alexandra; Millard, Monica; Kroll, Jason; Dally, Len; Hoelscher, Michael; Bailer, Robert; Cox, Josephine H.; Marovich, Mary; Birx, Deborah L. // Journal of Infectious Diseases;2/15/2010, Vol. 201 Issue 4, p600 

    Background. Human immunodeficiency virus (HIV) vaccine development remains a global priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a replication-defective recombinant adenovirus serotype 5 (rAd5) boost. Methods. The vaccine is a 6-plasmid mixture...

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Travel Medicine Advisor;Nov2007, Vol. 17 Issue 11, p2 

    The article reports on the ineffectiveness of HIV vaccine from Merck in a large clinical trial that made the company halt further test vaccinations. A trial which was started in 2004 has identified 24 new HIV infections in the group who received the vaccine compared to 21 infections in the...

  • Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally. Lewis, David J.; Fraser, Carol A.; Mahmoud, Abdel N.; Wiggins, Rebecca C.; Woodrow, Maria; Cope, Alethea; Chun Cai; Giemza, Rafaela; Jeffs, Simon A.; Manoussaka, Maria; Cole, Tom; Cranage, Martin P.; Shattock, Robin J.; Lacey, Charles J. // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    We conducted a phase 1 double-blind randomised controlled trial (RCT) of a HIV-1 envelope protein (CN54 gp140) candidate vaccine delivered vaginally to assess immunogenicity and safety. It was hypothesised that repeated delivery of gp140 may facilitate antigen uptake and presentation at this...

  • HIV vaccine reduces infection rate by a third, randomised trial of 16 400 shows. Mayor, Susan // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/3/2009, Vol. 339 Issue 7724, p772 

    The article reports on the results of a study released by the U.S. Military HIV Research Program which evaluated the efficacy of an experimental vaccine in preventing HIV infection aside from its ability to reduce the amount of HIV in the blood of those who became infected after vaccination. The...

  • Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand. Pitisuttithum, Punnee; Gilbert, Peter; Gurwith, Marc; Heyward, William; Martin, Michael; van Griensven, Fritz; Hu, Dale; Tappero, Jordan W.; Choopanya, Kachit // Journal of Infectious Diseases;12/15/2006, Vol. 194 Issue 12, p1661 

    Background. In Thailand, phase 1/2 trials of monovalent subtype B and bivalent subtype B/E (CRF01_AE) recombinant glycoprotein 120 human immunodeficiency virus type 1 (HIV-1) vaccines were successfully conducted from 1995 to 1998, prompting the first HIV-1 vaccine efficacy trial in Asia....

  • An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers. Van Braeckel, Eva; Bourguignon, Patricia; Koutsoukos, Marguerite; Clement, Frédéric; Janssens, Michel; Carletti, Isabelle; Collard, Alix; Demoitié, Marie-Ange; Voss, Gerald; Leroux-Roels, Geert; McNally, Lisa // Clinical Infectious Diseases;2/15/2011, Vol. 52 Issue 4, p522 

    Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety and immunogenicity of a novel human immunodeficiency virus type 1 (HIV-1) vaccine candidate consisting of a recombinant fusion protein (F4) containing 4 HIV-1 clade B antigens (Gag p24, Pol reverse...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics